A combination ophthalmic suspension designed to treat glaucoma and ocular hypertension has been launched in Japan, according to a press release.
Ailamide (brimonidine tartrate/brinzolamide) is the first combination ophthalmic suspension in Japan for the treatment of glaucoma and ocular hypertension that does not have beta-blockers. It was approved for use in March.
The drug is expected to improve patient adherence by replacing multidrug therapies. One drop is instilled in the eye twice daily.
Senju Pharmaceutical Co. is the marketing authorization holder of the drug, while collaborator Otsuka